Reuters logo
BRIEF-Teva receives FDA priority review for first line use of Trisenox
2017年9月12日 / 中午12点23分 / 13 天前

BRIEF-Teva receives FDA priority review for first line use of Trisenox

Sept 12 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva receives fda priority review for first line use of trisenox® (arsenic trioxide) in patients with low to intermediate risk acute promyelocytic leukemia (apl)

* Teva Pharmaceutical Industries Ltd - ‍FDA has accepted SNDA for priority review with regulatory action expected in Q1 of 2018​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below